1. Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada.
- Author
-
Vanderpuye-Orgle J, Erim D, Qian Y, Boyne DJ, Cheung WY, Bebb G, Shah A, Pericleous L, Maruszczak M, and Brenner DR
- Abstract
Introduction: New requirements in Canada's pricing processes for patented drugs may exacerbate delays in regulatory and reimbursement reviews. This study seeks to better understand the impact of any additional delays on non-small cell lung cancer (NSCLC) patients by measuring the following: (a) durations and outcomes of regulatory and reimbursement reviews of NSCLC drugs in Canada and reference countries; (b) delays in Canada's reviews of three NSCLC drugs (nivolumab, afatinib, and pemetrexed [NAP]); and (c) estimating clinical, patient, and economic impacts of delays in Canada's reviews on access to NAP., Methods: Information from the Context Matters database and the literature (2005-2020) was used to evaluate the durations and outcomes of reimbursement reviews of NSCLC drugs in Canada and comparator countries. Public information was used to assess delays in Canada's reviews of NAP. Empirical modeling with data from the literature and the Southern Alberta Lung Cancer database was used to estimate the impact of delays in Canada's NAP reviews on patients (i.e., as losses in person-years of life and quality-adjusted life-years [QALYs])., Results: Regulatory and reimbursement reviews in countries of interest take 12-18 months. In Canada, reviews of NSCLC drugs took 216 days (median), with a 24% rejection rate (mean = 19%). Delays in NAP reviews ranged from 5 to 94 days at Health Canada, 0-80 days at CADTH/pCODR, and 12-797 days in Canadian provinces. These delays may have affected 6400 patients, who lost up to 1740 person-years of life and 1122 QALYs (valued at CA$112 million)., Conclusion: Changes to Canada's prescription drug pricing processes may prolong reviews., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF